| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Westlake BioPartners Fund I, L.P. | 7.8% | $43,778,216 | 4,657,257 | Dr. Beth C. Seidenberg ("Seidenberg") | 31 Dec 2025 | |||
| Northpond Ventures III, LP | 6.1% | $28,531,978 | 3,466,826 | Michael P. Rubin | 31 Dec 2025 | |||
| Bain Capital Life Sciences Opportunities III, LP | 5.4% | $25,595,300 | 3,110,000 | Bain Capital Life Sciences Opportunities III, LP | 31 Dec 2025 | |||
| GordonMD Global Investments LP | 7% | $23,275,071 | 3,058,485 | GordonMD Global Investments LP | 13 Nov 2025 |
As of 31 Dec 2025, 98 institutional investors reported holding 33,999,157 shares of Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX). This represents 60% of the company’s total 56,833,213 outstanding shares.
The largest institutional shareholders of Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX) together control 52% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| GordonMD Global Investments LP | 7.7% | 4,391,818 | 0% | 30% | $41,283,089 |
| GILEAD SCIENCES, INC. | 7.3% | 4,126,119 | 0% | 2% | $38,785,519 |
| Bain Capital Life Sciences Investors, LLC | 5.5% | 3,110,000 | -7.7% | 2.2% | $29,234,000 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3.5% | 2,000,000 | 0.24% | $18,800,000 | |
| VANGUARD GROUP INC | 3.1% | 1,781,257 | +35% | 0% | $16,743,815 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.1% | 1,762,617 | +17% | 0% | $16,569,000 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.9% | 1,666,666 | 0.02% | $15,666,660 | |
| AIGH Capital Management LLC | 2.6% | 1,500,000 | 4.2% | $14,100,000 | |
| MORGAN STANLEY | 1.8% | 1,002,495 | +475% | 0% | $9,423,453 |
| Insight Holdings Group, LLC | 1.7% | 989,054 | 0% | 0.7% | $9,297,108 |
| Balyasny Asset Management L.P. | 1.7% | 980,869 | 0.02% | $9,220,169 | |
| Woodline Partners LP | 1.5% | 845,143 | +235% | 0.03% | $7,944,344 |
| Propel Bio Management, LLC | 1.2% | 666,666 | 5.4% | $6,266,660 | |
| MBB PUBLIC MARKETS I LLC | 1.1% | 614,477 | 0% | 0.6% | $5,776,084 |
| Alyeska Investment Group, L.P. | 1.1% | 600,000 | 0.02% | $5,640,000 | |
| MILLENNIUM MANAGEMENT LLC | 1% | 593,369 | +7.6% | 0% | $5,577,669 |
| BlackRock, Inc. | 0.96% | 544,539 | +13% | 0% | $5,118,666 |
| D. E. Shaw & Co., Inc. | 0.91% | 518,512 | 0% | $4,874,013 | |
| RFG Advisory, LLC | 0.78% | 445,200 | 0.08% | $4,184,880 | |
| CITADEL ADVISORS LLC | 0.48% | 275,446 | +1459% | 0% | $2,589,192 |
| HEIGHTS CAPITAL MANAGEMENT, INC | 0.48% | 271,822 | 0.97% | $2,555,127 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.47% | 266,402 | -4.3% | 0% | $2,505,726 |
| BNP PARIBAS FINANCIAL MARKETS | 0.44% | 252,151 | 0% | 0% | $2,370,219 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.42% | 238,828 | +18% | 0% | $2,244,983 |
| TD Asset Management Inc | 0.39% | 222,796 | +35% | 0% | $2,094,282 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 33,999,157 | $319,713,076 | +$113,479,794 | $9.40 | 98 |
| 2025 Q3 | 22,688,863 | $136,134,153 | -$2,158,017 | $6.00 | 74 |
| 2025 Q2 | 23,200,134 | $71,227,727 | -$5,373,744 | $3.07 | 77 |
| 2025 Q1 | 25,800,890 | $49,797,231 | -$8,775,592 | $1.93 | 86 |
| 2024 Q4 | 28,863,400 | $107,952,189 | -$6,920,913 | $3.74 | 87 |
| 2024 Q3 | 28,136,737 | $138,294,516 | -$28,965,516 | $4.89 | 92 |
| 2024 Q2 | 31,935,411 | $239,516,646 | -$86,044,405 | $7.50 | 87 |
| 2024 Q1 | 30,688,965 | $762,283,849 | +$760,773,578 | $24.84 | 88 |